ExPASy logo ExPASy Home page Site Map Search ExPASy Contact us Swiss-Prot
Notice: This page will be replaced with www.uniprot.org. Please send us your feedback!
Search for

UniProtKB/Swiss-Prot entry P26660


[Entry info] [Name and origin] [References] [Comments] [Cross-references] [Keywords] [Features] [Sequence] [Tools]

Note: most headings are clickable, even if they don't appear as links. They link to the user manual or other documents.
Entry information
Entry name POLG_HCVJ6
Primary accession number P26660
Secondary accession numbers None
Integrated into Swiss-Prot on August 1, 1992
Sequence was last modified on January 23, 2007 (Sequence version 3)
Annotations were last modified on    July 22, 2008 (Entry version 89)
Name and origin of the protein
Protein name Genome polyprotein
Synonyms None
Contains Core protein p21
     (Capsid protein C)
     (p21)
Core protein p19
Envelope glycoprotein E1
     (gp32)
     (gp35)
Envelope glycoprotein E2
     (NS1)
     (gp68)
     (gp70)
p7
Protease NS2-3
     (p23)
     (EC 3.4.22.-)
Serine protease/NTPase/helicase NS3
     (EC 3.4.21.98)
     (EC 3.6.1.15)
     (EC 3.6.1.-)
     (Hepacivirin)
     (NS3P)
     (p70)
Non-structural protein 4A
     (NS4A)
     (p8)
Non-structural protein 4B
     (NS4B)
     (p27)
Non-structural protein 5A
     (NS5A)
     (p56)
RNA-directed RNA polymerase
     (EC 2.7.7.48)
     (NS5B)
     (p68)
Gene name None
From
Hepatitis C virus genotype 2a (isolate HC-J6) (HCV) [TaxID: 11113] 
Taxonomy Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae; Hepacivirus.
Virus host Homo sapiens (Human) [TaxID: 9606]
Protein existence 1: Evidence at protein level;
References
[1]
NUCLEOTIDE SEQUENCE [GENOMIC RNA].
PubMed=1658196 [NCBI, ExPASy, EBI, Israel, Japan]
Okamoto H., Okada S., Sugiyama Y., Kurai K., Lizuka H., Machida A., Miyakawa Y., Mayumi M.;
"Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions.";
J. Gen. Virol. 72:2697-2704(1991).
[2]
INTERACTION WITH HUMAN CLDN1.
DOI=10.1038/nature05654; PubMed=17325668 [NCBI, ExPASy, EBI, Israel, Japan]
Evans M.J., von Hahn T., Tscherne D.M., Syder A.J., Panis M., Wolk B., Hatziioannou T., McKeating J.A., Bieniasz P.D., Rice C.M.;
"Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.";
Nature 446:801-805(2007).
[3]
REVIEW.
DOI=10.1046/j.1365-2893.2000.00201.x; PubMed=10718937 [NCBI, ExPASy, EBI, Israel, Japan]
McLauchlan J.;
"Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes.";
J. Viral Hepat. 7:2-14(2000).
[4]
REVIEW, AND SUBCELLULAR LOCATION.
DOI=10.1002/hep.20032; PubMed=14752815 [NCBI, ExPASy, EBI, Israel, Japan]
Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
"Structural biology of hepatitis C virus.";
Hepatology 39:5-19(2004).
[5]
X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 2443-3012.
DOI=10.1074/jbc.M413410200; PubMed=15746101 [NCBI, ExPASy, EBI, Israel, Japan]
Biswal B.K., Cherney M.M., Wang M., Chan L., Yannopoulos C.G., Bilimoria D., Nicolas O., Bedard J., James M.N.G.;
"Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors.";
J. Biol. Chem. 280:18202-18210(2005).
Comments
  • FUNCTION: Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).
  • FUNCTION: E1 and E2 glycoproteins form a heterodimer that is involved in virus attachment to the host cell, virion internalization through clathrin-dependent endocytosis and fusion with host membrane. E1/E2 heterodimer binds to human LDLR, CD81 and SCARB1/SR-BI receptors, but this binding is not sufficient for infection, some additional liver specific cofactors may be needed. The fusion function may possibly be carried by E1. E2 inhibits human EIF2AK2/PKR activation, preventing the establishment of an antiviral state. E2 is a viral ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on liver sinusoidal endothelial cells and macrophage-like cells of lymph node sinuses. These interactions allow capture of circulating HCV particles by these cells and subsequent transmission to permissive cells. DCs act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. Capture of circulating HCV particles by these SIGN+ cells may facilitate virus infection of proximal hepatocytes and lymphocyte subpopulations and may be essential for the establishment of persistent infection (By similarity).
  • FUNCTION: P7 seems to be a heptameric ion channel protein (viroporin) and is inhibited by the antiviral drug amantadine. Also inhibited by long-alkyl-chain iminosugar derivatives. Essential for infectivity (By similarity).
  • FUNCTION: Protease NS2-3 is a cysteine protease responsible for the autocatalytic cleavage of NS2-NS3. Seems to undergo self-inactivation following maturation (By similarity).
  • FUNCTION: NS3 displays three enzymatic activities: serine protease, NTPase and RNA helicase. NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand. Cleaves the host antiviral protein MAVS (By similarity). NS3/NS4A complex also prevents phosphorylation of human IRF3, thus preventing the establishment of dsRNA induced antiviral state.
  • FUNCTION: NS4B induces a specific membrane alteration that serves as a scaffold for the virus replication complex. This membrane alteration gives rise to the so-called ER-derived membranous web that contains the replication complex (By similarity).
  • FUNCTION: NS5A is a component of the replication complex involved in RNA-binding. Its interaction with Human VAPB may target the viral replication complex to vesicles. Down-regulates viral IRES translation initiation. Mediates interferon resistance, presumably by interacting with and inhibiting human EIF2AK2/PKR. Seems to inhibit apoptosis by interacting with BIN1 and FKBP8. The hyperphosphorylated form of NS5A is an inhibitor of viral replication (By similarity).
  • FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an essential role in the virus replication (By similarity).
  • CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral precursor polyprotein, commonly with Asp or Glu in the P6 position, Cys or Thr in P1 and Ser or Ala in P1'.
  • CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1).
  • CATALYTIC ACTIVITY: NTP + H2O = NDP + phosphate.
  • COFACTOR: Binds 1 zinc ion per NS3 protease domain (By similarity).
  • COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By similarity).
  • ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on zinc ions and completely inhibited by EDTA. Serine protease NS3 is also activated by zinc ions (By similarity).
  • SUBUNIT: Core protein is a homomultimer that binds the C-terminal part of E1 and interacts with numerous cellular proteins. Interaction with human STAT1 SH2 domain seems to result in decreased STAT1 phosphorylation, leading to decreased IFN-stimulated gene transcription. In addition to blocking the formation of phosphorylated STAT1, the core protein also promotes ubiquitin-mediated proteasome-dependent degradation of STAT1. Interacts with, and constitutively activates human STAT3. Associates with human LTBR and TNFRSF1A receptors and possibly induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK, C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins. Interacts with human CREB3 nuclear transcription protein, triggering cell transformation. May interact with human p53. Also binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1 and E2 glycoproteins form a heterodimer that binds to human LDLR, CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR. p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing a pair of composite active sites at the dimerization interface. NS2 seems to interact with all other non-structural (NS) proteins. NS4A interacts with NS3 serine protease and stabilizes its folding. NS3-NS4A complex is essential for the activation of the latter and allows membrane anchorage of NS3. NS3 interacts with human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form homodimers and seem to interact with all other non-structural (NS) proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2, BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B is a homooligomer and interacts with human VAPB (By similarity).
  • INTERACTION:
    P06241:FYN (xeno); NbExp=1; IntAct=EBI-706322, EBI-515315;
    P62993:GRB2 (xeno); NbExp=1; IntAct=EBI-706322, EBI-401755;
    P08631:HCK (xeno); NbExp=1; IntAct=EBI-706322, EBI-346340;
    P06240:Lck (xeno); NbExp=1; IntAct=EBI-706322, EBI-1401;
    P07948:LYN (xeno); NbExp=1; IntAct=EBI-706322, EBI-79452;
  • SUBCELLULAR LOCATION: Core protein p21: Endoplasmic reticulum membrane; Single-pass membrane protein (By similarity). Mitochondrion membrane; Single-pass type I membrane protein (By similarity). Lipid droplet membrane; Single-pass membrane protein (By similarity). Note=The C-terminal transmembrane domain of core protein p21 contains an ER signal leading the nascent polyprotein to the ER membrane. Only a minor proportion of core protein is present in the nucleus and an unknown proportion is secreted.
  • SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity). Cytoplasm (By similarity). Nucleus (By similarity). Secreted (By similarity).
  • SUBCELLULAR LOCATION: Envelope glycoprotein E1: Endoplasmic reticulum membrane; Single-pass type I membrane protein (By similarity). Note=The C-terminal transmembrane domain acts as a signal sequence and forms a hairpin structure before cleavage by host signal peptidase. After cleavage, the membrane sequence is retained at the C-terminus of the protein, serving as ER membrane anchor. A reorientation of the second hydrophobic stretch occurs after cleavage producing a single reoriented transmembrane domain. These events explain the final topology of the protein. ER retention of E1 is leaky and, in overexpression conditions, only a small fraction reaches the plasma membrane.
  • SUBCELLULAR LOCATION: Envelope glycoprotein E2: Endoplasmic reticulum membrane; Single-pass type I membrane protein (By similarity). Note=The C-terminal transmembrane domain acts as a signal sequence and forms a hairpin structure before cleavage by host signal peptidase. After cleavage, the membrane sequence is retained at the C-terminus of the protein, serving as ER membrane anchor. A reorientation of the second hydrophobic stretch occurs after cleavage producing a single reoriented transmembrane domain. These events explain the final topology of the protein. ER retention of E2 is leaky and, in overexpression conditions, only a small fraction reaches the plasma membrane.
  • SUBCELLULAR LOCATION: p7: Endoplasmic reticulum membrane; Multi-pass membrane protein (By similarity). Cell membrane (By similarity). Note=The C-terminus of p7 membrane domain acts as a signal sequence. After cleavage by host signal peptidase, the membrane sequence is retained at the C-terminus of the protein, serving as ER membrane anchor. Only a fraction localizes to the plasma membrane.
  • SUBCELLULAR LOCATION: Protease NS2-3: Endoplasmic reticulum membrane; Multi-pass membrane protein (Potential).
  • SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Endoplasmic reticulum membrane; Peripheral membrane protein (By similarity). Note=NS3 is associated to the ER membrane through its binding to NS4A.
  • SUBCELLULAR LOCATION: Non-structural protein 4A: Endoplasmic reticulum membrane; Single-pass type I membrane protein (Potential). Note=Membrane insertion occurs after processing by the NS3 protease.
  • SUBCELLULAR LOCATION: Non-structural protein 4B: Endoplasmic reticulum membrane; Multi-pass membrane protein (By similarity).
  • SUBCELLULAR LOCATION: Non-structural protein 5A: Endoplasmic reticulum membrane; Peripheral membrane protein (By similarity). Cytoplasm, perinuclear region (By similarity). Mitochondrion (By similarity). Note=Membrane insertion occurs after processing by the NS3 protease.
  • SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Endoplasmic reticulum membrane; Single-pass type I membrane protein (Potential). Note=Membrane insertion occurs after processing by the NS3 protease.
  • DOMAIN: The transmembrane regions of envelope E1 and E2 glycoproteins are involved in heterodimer formation, ER localization, and assembly of these proteins. Envelope E2 glycoprotein contain a highly variable region called hypervariable region 1 (HVR1). E2 also contains two segments involved in CD81-binding. HVR1 is implicated in the SCARB1-mediated cell entry. CD81-binding regions may be involved in sensitivity and/or resistance to IFN-alpha therapy (By similarity).
  • DOMAIN: The N-terminus of NS5A acts as membrane anchor. The central part of NS5A seems to be intrinsically disordered and interacts with NS5B and host PKR (By similarity).
  • DOMAIN: The SH3-binding domain of NS5A is involved in the interaction with human Bin1, GRB2 and Src-family kinases (By similarity).
  • DOMAIN: The N-terminal one-third of serine protease NS3 contains the protease activity. This region contains a zinc atom that does not belong to the active site, but may play a structural rather than a catalytic role. This region is essential for the activity of protease NS2-3, maybe by contributing to the folding of the latter. The helicase activity is located in the C-terminus of NS3 (By similarity).
  • PTM: Specific enzymatic cleavages in vivo yield mature proteins. The structural proteins, core, E1, E2 and p7 are produced by proteolytic processing by host signal peptidases. The core protein is synthesized as a 21 kDa precursor which is retained in the ER membrane through the hydrophobic signal peptide. Cleavage by the signal peptidase releases the 19 kDa mature core protein. The other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are cleaved by the viral proteases (By similarity).
  • PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated (By similarity).
  • PTM: Core protein is phosphorylated by host PKC and PKA (By similarity).
  • PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an hyperphosphorylated form of p56. p56 and p58 coexist in the cell in roughly equivalent amounts. Hyperphosphorylation is dependent on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1, MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for NS5A phosphorylation (By similarity).
  • PTM: NS4B is palmitoylated. This modification may play a role in its polymerization or in protein-protein interactions (By similarity).
  • PTM: The N-terminus of a fraction of NS4B molecules seems to be relocated post-translationally from the cytoplasm to the ER lumen, with a 5th transmembrane segment. The C-terminus of NS2 may be lumenal with a fourth transmembrane segment (By similarity).
  • PTM: Core protein is ubiquitinated; mediated by UBE3A and leading to core protein subsequent proteasomal degradation (By similarity).
  • MISCELLANEOUS: Cell culture adaptation of the virus leads to mutations in NS5A, reducing its inhibitory effect on replication (By similarity).
  • MISCELLANEOUS: Core protein exerts viral interference on hepatitis B virus when HCV and HBV coinfect the same cell, by suppressing HBV gene expression, RNA encapsidation and budding (By similarity).
  • SIMILARITY: Belongs to the hepaciviruses polyprotein family.
  • SIMILARITY: Contains 1 helicase ATP-binding domain.
  • SIMILARITY: Contains 1 peptidase C18 domain [view classification].
  • SIMILARITY: Contains 1 peptidase S29 domain [view classification].
  • SIMILARITY: Contains 1 RdRp catalytic domain.
  • CAUTION: The core gene probably also codes for alternative reading frame proteins (ARFPs). Many functions depicted for the core protein might belong to the ARFPs.
  • WEB RESOURCE: Name=euHCVdb; Note=The European HCV database; URL="http://euhcvdb.ibcp.fr";.
  • WEB RESOURCE: Name=HCV databases; URL="http://hcv.lanl.gov/content/hcv-db/";.
Copyright
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms. Distributed under the Creative Commons Attribution-NoDerivs License.
Cross-references
Sequence databases
EMBL
D00944; BAA00792.1; -; Genomic_RNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
PIR JQ1303; JQ1303.
3D structure databases
PDB
1YUY; X-ray; 1.90 A; A=2443-3012.[ExPASy / RCSB / EBI]
1YV2; X-ray; 2.50 A; A=2443-3012.[ExPASy / RCSB / EBI]
1YVX; X-ray; 2.00 A; A=2443-3012.[ExPASy / RCSB / EBI]
1YVZ; X-ray; 2.20 A; A=2443-3012.[ExPASy / RCSB / EBI]
Detailed list of linked structures.
PDBsum 1YUY; -.
1YV2; -.
1YVX; -.
1YVZ; -.
SMR P26660; 1032-1660, 1033-1661, 2442-3003.
ModBase P26660.
Protein-protein interaction databases
IntAct P26660; -.
Organism-specific databases
euHCVdb D00944; -.
Ontologies
GO
GO:0005515; Molecular function: protein binding (inferred from physical interaction from IntAct).
QuickGo view.
Family and domain databases
InterPro IPR014001; DEAD-like_N.
IPR001650; DNA/RNA_helicase_C.
IPR002522; HCV_capsid.
IPR002521; HCV_core.
IPR002519; HCV_env.
IPR002531; HCV_NS1.
IPR000745; HCV_NS4a.
IPR001490; HCV_NS4b.
IPR002868; HCV_NS5a.
IPR013193; HCV_NS5a_1b.
IPR014021; Helicase_SF1/SF2_ATP-bd.
IPR002518; Pept_C18_HCV_NS2.
IPR004109; Peptidase_S29.
IPR002166; RNA_pol_HCV.
IPR007094; RNA_pol_PSvir.
IPR013192; Znf_HCV_NS5a.
Graphical view of domain structure.
Pfam PF01543; HCV_capsid; 1.
PF01542; HCV_core; 1.
PF01539; HCV_env; 1.
PF01560; HCV_NS1; 1.
PF01538; HCV_NS2; 1.
PF01006; HCV_NS4a; 1.
PF01001; HCV_NS4b; 1.
PF01506; HCV_NS5a; 1.
PF08300; HCV_NS5a_1a; 1.
PF08301; HCV_NS5a_1b; 1.
PF02907; Peptidase_S29; 1.
PF00998; RdRP_3; 1.
Pfam graphical view of domain structure.
SMART SM00487; DEXDc; 1.
SMART graphical view of domain structure.
PROSITE PS51192; HELICASE_ATP_BIND_1; 1.
PS51194; HELICASE_CTER; FALSE_NEG.
PS50507; RDRP_SSRNA_POS; 1.
PROSITE graphical view of domain structure (profiles).
BLOCKS P26660.
Other
LinkHub P26660; -.
ProtoNet P26660.
UniRef View cluster of proteins with at least 50% / 90% / 100% identity.
Keywords
3D-structure; Acetylation; Apoptosis; ATP-binding; Capsid protein; Cell membrane; Complete proteome; Cytoplasm; Endoplasmic reticulum; Envelope protein; Fusion protein; Glycoprotein; Helicase; Host-virus interaction; Hydrolase; Interferon antiviral system evasion; Lipid droplet; Lipoprotein; Membrane; Metal-binding; Mitochondrion; Multifunctional enzyme; Nucleotide-binding; Nucleotidyltransferase; Nucleus; Oncogene; Palmitate; Phosphoprotein; Protease; Ribonucleoprotein; RNA replication; RNA-binding; RNA-directed RNA polymerase; Secreted; Serine protease; Thiol protease; Transcription; Transcription regulation; Transferase; Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
Features
SEVIEWER logo Feature table viewer FT aligner logo Feature aligner
KeyFrom    To Length Description FTId
INIT_MET   1      1        Removed; by host (By similarity). 
CHAIN   2    191  190     Core protein p21 (Potential). PRO_0000037608
CHAIN   2    177  176     Core protein p19 (By similarity). PRO_0000037609
PROPEP   178    191  14     ER anchor for the core protein, removed in mature form by host signal peptidase (By similarity). PRO_0000037610
CHAIN   192    383  192     Envelope glycoprotein E1 (Potential). PRO_0000037611
CHAIN   384    750  367     Envelope glycoprotein E2 (Potential). PRO_0000037612
CHAIN   751    813  63     p7 (By similarity). PRO_0000037613
CHAIN   814   1030  217     Protease NS2-3 (Potential). PRO_0000037614
CHAIN   1031   1661  631     Serine protease/NTPase/helicase NS3 (Potential). PRO_0000037615
CHAIN   1662   1715  54     Non-structural protein 4A (Potential). PRO_0000037616
CHAIN   1716   1976  261     Non-structural protein 4B (Potential). PRO_0000037617
CHAIN   1977   2442  466     Non-structural protein 5A (Potential). PRO_0000037618
CHAIN   2443   3033  591     RNA-directed RNA polymerase (Potential). PRO_0000037619
TOPO_DOM   2    168  167     Cytoplasmic (Potential). 
TRANSMEM   169    189  21     Potential. 
TOPO_DOM   190    358  169     Lumenal (Potential). 
TRANSMEM   359    379  21     Potential. 
TOPO_DOM   380    729  350     Lumenal (Potential). 
TRANSMEM   730    750  21     Potential. 
TOPO_DOM   751    761  11     Lumenal (Potential). 
TRANSMEM   762    782  21     Potential. 
TOPO_DOM   783    786  4     Cytoplasmic (Potential). 
TRANSMEM   787    807  21     Potential. 
TOPO_DOM   808    817  10     Lumenal (Potential). 
TRANSMEM   818    838  21     Potential. 
TOPO_DOM   839    885  47     Cytoplasmic (Potential). 
TRANSMEM   886    906  21     Potential. 
TOPO_DOM   907    932  26     Lumenal (Potential). 
TRANSMEM   933    953  21     Potential. 
TOPO_DOM   954   1661  708     Cytoplasmic (Potential). 
TRANSMEM   1662   1682  21     Potential. 
TOPO_DOM   1683   1809  127     Cytoplasmic (Potential). 
TRANSMEM   1810   1830  21     Potential. 
TOPO_DOM   1831   1832  2     Lumenal (Potential). 
TRANSMEM   1833   1853  21     Potential. 
TOPO_DOM   1854   1854  1     Cytoplasmic (Potential). 
TRANSMEM   1855   1875  21     Potential. 
TOPO_DOM   1876   1885  10     Lumenal (Potential). 
TRANSMEM   1886   1906  21     Potential. 
TOPO_DOM   1907   1976  70     Cytoplasmic (Potential). 
TOPO_DOM   1977   2006  30     In membrane (By similarity). 
TOPO_DOM   2007   3012  1006     Cytoplasmic (Potential). 
TRANSMEM   3013   3033  21     By similarity. 
DOMAIN   1221   1373  153     Helicase ATP-binding. 
DOMAIN   2656   2774  119     RdRp catalytic. 
NP_BIND   1234   1241  8     ATP (Potential). 
REGION   2     59  58     Interaction with DDX3X (By similarity). 
REGION   2     23  22     Interaction with STAT1 (By similarity). 
REGION   122    173  52     Interaction with APOA2 (By similarity). 
REGION   150    159  10     Mitochondrial targeting signal (By similarity). 
REGION   164    167  4     Important for lipid droplets localization (By similarity). 
REGION   265    296  32     Fusion peptide (Potential). 
REGION   385    411  27     HVR1 (By similarity).